0002108359 2026-08-27 2026-08-27 true 0002108359 8-K/A 2026-08-27 BIOKEY (CAYMAN), INC. E9 000-56853 93-3535498 44370 Old Warm Springs Blvd. Fremont CA 94538 510 668-0881 false false false false true false Earlier today, BioKey (Cayman), Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), filed a Current Report on Form 8-K (the “Initial 8K”) to disclose that it has successfully completed the separation (the “Spin-Off”) from ABVC BioPharma, Inc. (“ABVC”), effected by ABVC’s distribution of approximately 15% of the issued and outstanding ordinary shares, par value $0.0001 per share (“Ordinary Shares”), of the Company to holders of common stock of ABVC (the “ABVC Common Stockholders”) as a pro rata dividend in the Spin-Off (the “Distribution”), pursuant to the terms of that certain Separation and Distribution Agreement, dated as of June 22, 2026, between the Company and ABVC (the “Separation Agreement”). Attached as Exhibit 99.1 to the Initial 8K, was the final form of the information statement that describes the Spin-Off and provides important information regarding the Company’s business and management (the “Information Statement”), however it was not dated. We are filing this amendment to the Initial 8K solely to attach the final, dated Information Statement. Other than the date, there are no changes to the Information Statement.